AbbVie Inc (ABBV)vsZevra Therapeutics Inc. (ZVRA)
ABBV
AbbVie Inc
$288.70
-2.24%
HEALTHCARE · Cap: $521.11B
ZVRA
Zevra Therapeutics Inc.
$10.53
-5.73%
HEALTHCARE · Cap: $597.10M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 48414% more annual revenue ($66.01B vs $136.07M). ZVRA leads profitability with a 42.8% profit margin vs 15.7%. ABBV appears more attractively valued with a PEG of 0.60. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
ZVRA
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.0%
Fair Value
$156.84
Current Price
$288.69
$131.85 premium
Margin of Safety
+64.0%
Fair Value
$23.52
Current Price
$10.53
$12.99 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Attractively priced relative to earnings
Keeps 43 of every $100 in revenue as profit
Strong operational efficiency at 42.3%
Revenue surging 53.3% year-over-year
Conservative balance sheet, low leverage
Every $100 of equity generates 27 in profit
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
Expensive relative to growth rate
Earnings declined 88.4%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : ZVRA
The strongest argument for ZVRA centers on P/E Ratio, Profit Margin, Operating Margin. Profitability is solid with margins at 42.8% and operating margin at 42.3%. Revenue growth of 53.3% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : ZVRA
The primary concerns for ZVRA are Market Cap, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
ABBV profiles as a mature stock while ZVRA is a growth play — different risk/reward profiles.
ZVRA carries more volatility with a beta of 0.98 — expect wider price swings.
ZVRA is growing revenue faster at 53.3% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 66/100), backed by strong 15.7% margins and 10.3% revenue growth. ZVRA offers better value entry with a 64.0% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Zevra Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?